Hemab Therapeutics raises $135m for prophylactic treatments for bleeding and thrombotic disorders

Hemab Therapeutics, a clinical-stage biotechnology company, has raised $135 million in a Series B financing round for advancing prophylactic treatments for underserved bleeding and thrombotic ... Read More